Is BRCA2 p.Met784Val (c.2350A>G) pathogenic?

BRCA2 p.Met784Val (c.2350A>G) is classified Benign in BRCA2 (ClinVar, Expert panel, 28 submitters; last evaluated 2015-01-12). AlphaMissense: likely benign (0.0653); Low-frequency (popmax 4.84%, eas); Associated with breast-ovarian cancer, familial, susceptibility to, 2.

What condition is associated with BRCA2 p.Met784Val (c.2350A>G)?

BRCA2 p.Met784Val (c.2350A>G) is associated with breast-ovarian cancer, familial, susceptibility to, 2, hereditary breast ovarian cancer syndrome, breast cancer (ClinVar).

How common is BRCA2 p.Met784Val (c.2350A>G) in the general population?

BRCA2 p.Met784Val (c.2350A>G) is low-frequency (popmax 4.84%, eas) (gnomAD).

How is Hereditary breast and/or ovarian cancer syndrome inherited?

Typically Autosomal dominant (Orphanet). A genetic counselor can assess individual risk for a family.

What do computational predictors say about BRCA2 p.Met784Val (c.2350A>G)?

AlphaMissense predicts likely benign (score 0.0653) — an in-silico prediction, not a clinical call.

BRCA2 p.Met784Val

c.2350A>G · rs11571653 · VCV41544

Benign Expert panel

Classification

Benign

ClinVar

Review

Expert panel ★★★☆

ClinVar · 28 submitters

AlphaMissense

likely benign

0.0653 · ACMG-weighted

gnomAD v4.1

Rare

low-frequency (popmax 4.84%, eas)

Missense predictors

0/2 damaging

AlphaMissense, REVEL · SaProt no call

Conditions

breast-ovarian cancer, familial, susceptibility to, 2

Computational evidence

Protein change
AlphaMissense	0.0653	likely benign
REVEL	0.202	benign-leaning
SaProt	—	not scored · why
⇒ AlphaMissense and REVEL both call this tolerated; SaProt makes no call.
Splicing
SpliceAI	<0.2	no splice effect predicted · four deltas, not one · how we know
Constraint at this position
Conservation	phyloP -0.43	GERP -4.6
Regional constraint	o/e 1.03	unconstrained · MANE · 47 kb · p 0.059 · regional, not allelic
Overall
CADD	0.006	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL is an independent agreement signal.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 4.84% East Asian · 2,173/44,862 alleles

Filtering AF 4.67% ClinGen BA1/BS1 input FAF95, joint · FAF99 4.61%

Overall 0.136% 2,191/1,614,048 alleles · low-frequency exomes 2,098/1,461,714 · genomes 93/152,334 · joint denominator

Ancestry group	Frequency	1 in
East Asiangrpmax	4.84%	21
Remaining individualsnot grpmax-eligible	0.0208%	4,808
Admixed American	0.00667%	15,002
South Asian	0.0011%	91,084

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: BRCA2
Protein: p.Met784Val
Coding: c.2350A>G
MANE Select: NM_000059
dbSNP: rs11571653
Type: single nucleotide variant
Location: chr13:32336705 (GRCh38)
Gene constraint: LOEUF 0.803 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Residue 784: the 'interaction with npm1' region; a UniProt-annotated variant site (in)

Full BRCA2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

breast-ovarian cancer, familial, susceptibility to, 2 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary breast ovarian cancer syndrome breast cancer ovarian cancer Fanconi anemia complementation group D1 hereditary neoplastic syndrome hereditary breast carcinoma breast neoplasm

For Hereditary breast and/or ovarian cancer syndrome (Orphanet):

Inheritance: Autosomal dominant
Onset: Adult, Elderly

Similar variants

BRCA2 p.Met784Arg Conflicting classifications of pathogenicity ★ same residue
BRCA2 p.Met784Ile Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Met784Lys Uncertain significance ★ same residue
BRCA2 p.Met784Thr Conflicting classifications of pathogenicity ★ same residue
BRCA2 p.Met784Leu Likely benign ★ same residue
BRCA2 c.316+1G>T Pathogenic ★★★ same condition
BRCA2 c.316+2T>C Pathogenic ★★★ same condition
BRCA2 c.316+5G>A Pathogenic ★★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca2-p-met784val (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown